“The first was in India with our partner Gennova Biopharmaceuticals which has moved the vaccine into Phase II and Phase III trials.” In addition, the company has other collaborations in place for the vaccine, including in China and South Korea. The vaccine of HDT Bio will also be analysed...
HDT has similar collaborations with Gennova Biopharmaceuticals in India, SENAI CIMATEC in Brazil and with a fourth company in China. Quratis is developing HDT Bio’s RNA vaccine under the name QTP104. The Phase 1 study is a randomized, open label, dose-escalation trial to evaluate ...
Translational Health Science and Technology Institute (THSTI), Faridabad, Haryana, India Amit Singhal Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA Hardy Kornfeld Corresponding authors Correspondence toAmit SinghalorHardy Kornfeld. ...